Literature DB >> 20007407

Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure.

David P Wilson1.   

Abstract

BACKGROUND: Exposures to sexually transmitted infections are discrete identifiable events. Interventions to prevent sexually transmitted infections have a certain probability of effectiveness in reducing risk in any given event.
PURPOSE: Randomized control trials for sexually transmitted infections interventions are designed to estimate the effectiveness in preventing acquisition of infection. Typically, randomized control trials are run over a specific period of time and incidence in the control arm is compared with incidence in an intervention arm. However, it is possible that the effectiveness of an intervention over the duration of a clinical trial may be different to the actual effectiveness of the intervention in every single exposure event or the overall effectiveness over different periods than the duration of the trial.
METHODS: In this study a simple mathematical framework is used, similar to methods in conception research, to describe the expected effectiveness that would be observed in a clinical trial of an intervention per-exposure and for clinically relevant shorter and longer durations than the trial, where each subject has multiple risk exposures.
RESULTS: It is theoretically demonstrated that the actual effectiveness of the intervention per risk event is not equal to the overall preventative effectiveness of the intervention in preventing transmission over many exposures. Examples are given for sexually transmitted infections with diverse transmission probabilities (HIV and HPV) and for interventions with different levels of effectiveness (condoms and circumcision). The observed effectiveness of an intervention is likely to be maintained over many exposures for infections with low transmission risk (like HIV) but the observed effectiveness decreases substantially with number of exposures for moderate or high risk infections (like HPV). An equation is provided for interpreting randomized control trials' estimates of effectiveness with respect to various degrees of risk exposure. LIMITATIONS: The difficulty in adjusting the interpretation of randomized control trials results in this manner is that collection of accurate data on the number of discrete exposure events is not always possible and that there is substantial heterogeneity in degree of risk exposure between participants in trials.
CONCLUSIONS: The implications of this analysis are that common interpretations of clinical trial interventions are insufficient for understanding the true efficacy of an intervention in some circumstances. Estimates of effectiveness in trials may misrepresent effectiveness per exposure event and effectiveness over a lifetime of risk. Care should be taken when designing protocols for analysis of trial results when the expected incidence is high. No change to the current practice of designing randomized control trials is suggested but analysis of trial data could be extended to calculate other statistics of effectiveness. A type of extrapolation and interpolation method for estimating levels of effectiveness is proposed.

Entities:  

Mesh:

Year:  2009        PMID: 20007407     DOI: 10.1177/1740774509355177

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  5 in total

1.  Perceptions of Human Papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation.

Authors:  Massimo Giuliani; Maria Fenicia Vescio; Maria Gabriella Donà; Alessandra Latini; Mirko Frasca; Manuela Colafigli; Massimo Farinella; Giovanni Rezza; Antonio Cristaudo
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

2.  Estimating the effectiveness in HIV prevention trials by incorporating the exposure process: application to HPTN 035 data.

Authors:  Jingyang Zhang; Elizabeth R Brown
Journal:  Biometrics       Date:  2014-05-20       Impact factor: 2.571

3.  Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?

Authors:  Daniel Wood; Kathryn E Lancaster; Marie-Claude Boily; Kimberly A Powers; Deborah Donnell; Myron S Cohen; Dobromir T Dimitrov
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-01       Impact factor: 3.731

4.  Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials.

Authors:  Elizabeth R Brown; Clara P Dominguez Islas; Jingyang Zhang
Journal:  Stat Commun Infect Dis       Date:  2020-09-24

5.  Human papillomavirus infection: knowledge, attitudes, and behaviors among lesbian, gay men, and bisexual in Italy.

Authors:  Concetta P Pelullo; Gabriella Di Giuseppe; Italo F Angelillo
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.